- Home
- CB vs GNLX Comparison
CB vs GNLX Comparison
Compare CB & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$2.45
Company Overview
Basic Information| Metric | CB | GNLX |
|---|---|---|
| Founded | 1985 | 2001 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.7B | 113.6M |
| IPO Year | 1995 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CB | GNLX |
|---|---|---|
| Price | $319.68 | $2.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 5 |
| Target Price | ★ $331.90 | $19.80 |
| AVG Volume (30 Days) | ★ 1.5M | 155.5K |
| Earning Date | 04-21-2026 | 03-19-2026 |
| Dividend Yield | ★ 1.20% | N/A |
| EPS Growth | ★ 13.13 | 9.47 |
| EPS | ★ 25.68 | N/A |
| Revenue | ★ $59,402,000,000.00 | $8,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.31 | N/A |
| P/E Ratio | $12.61 | ★ N/A |
| Revenue Growth | ★ 6.54 | N/A |
| 52 Week Low | $264.10 | $1.99 |
| 52 Week High | $345.67 | $8.54 |
Technical Indicators
Market Signals| Indicator | CB | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 39.81 | 41.73 |
| Support Level | $293.54 | $2.33 |
| Resistance Level | $334.97 | $3.00 |
| Average True Range (ATR) | 5.19 | 0.15 |
| MACD | -1.34 | -0.00 |
| Stochastic Oscillator | 0.97 | 23.17 |
Price Performance
Historical Comparison CB
GNLX
About CB Chubb Limited
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination made the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.